NYSE$CHE
Chemed Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Chemed's Q3 2021 performance reflected a mix of challenges and growth, with revenue increase driven by Roto-Rooter's strong performance offsetting a decline in VITAS' revenue, and adjusted EPS showing a modest increase.
Chemed Corporation reported a 2.0% increase in revenue to $539 million. GAAP diluted EPS increased by 9.9% to $4.55, and adjusted diluted EPS increased by 4.1% to $5.06. The VITAS segment experienced a revenue decline, while Roto-Rooter demonstrated strong revenue growth.
- Consolidated revenue increased by 2.0% to $539 million.
- GAAP diluted EPS increased by 9.9% to $4.55.
- Adjusted diluted EPS increased by 4.1% to $5.06.
- Roto-Rooter's revenue increased by 15.7%, offsetting a decline in VITAS' revenue.
Headline financials
Revenue & EPS history
Chemed · Revenue · Quarterly
$539M
Revenue by segment
Chemed · $538M total across 2 segments · Q3 2021
- VITAS Healthcare$317M-5.9%58.9%
- Roto-Rooter$221M+15.7%41.1%
Forward guidance
Chemed anticipates full-year 2021 adjusted earnings per diluted share to be in the range of $19.00 to $19.20, compared to the initial guidance of $17.00 to $17.50. This revised guidance assumes an effective corporate tax rate on adjusted earnings of 25.1%. VITAS revenue is estimated to decline approximately 5%, and Roto-Rooter is forecasted to achieve full-year 2021 revenue growth of 17.3%.
Tailwinds
- Full-year 2021 adjusted earnings per diluted share are estimated to be in the range of $19.00 to $19.20.
- The revised guidance is higher than the initial 2021 adjusted earnings per diluted share guidance of $17.00 to $17.50.
- Roto-Rooter is forecasted to achieve full-year 2021 revenue growth of 17.3%.
- Roto-Rooter’s Adjusted EBITDA margin for 2021 is estimated to be between 28.5% to 29.0%.
- The company has successfully navigated within the rapidly changing environment during the pandemic.
Headwinds
- VITAS 2021 revenue, prior to Medicare Cap, is estimated to decline approximately 5% when compared to the prior year.
- Average Daily Census in 2021 is estimated to decline approximately 5.5%.
- Full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 18.8%.
- The pandemic will continue to disrupt the healthcare system and general economy.
- Future rules, regulations, and government mandates could materially impact the company’s ability to achieve the guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.7%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+2.1%
Avg return
30 days after
53%
36 / 68 earnings
Positive
+13.0%
Q3 2015
Best reaction
-14.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -0.1% | +4.0% | |
| Q4 2025 | -14.8% | -9.1% | -21.0% | |
| Q3 2025 | +6.0% | +0.4% | +0.1% | |
| Q1 2025 | -6.6% | -1.8% | -2.7% | |
| Q4 2024 | +7.4% | +7.7% | +11.0% | |
| Q3 2024 | -12.0% | -12.7% | -6.2% | |
| Q2 2024 | -0.1% | +2.4% | +5.7% | |
| Q1 2024 | -7.0% | -8.1% | -9.9% | |
| Q4 2023 | +5.1% | +2.6% | +7.3% | |
| Q3 2023 | +9.3% | +10.9% | +14.4% | |
| Q2 2023 | -8.1% | -8.0% | -10.8% | |
| Q1 2023 | -3.7% | -2.2% | -4.1% | |
| Q4 2022 | +3.3% | +1.7% | +1.9% | |
| Q3 2022 | +3.2% | +4.1% | +12.6% | |
| Q2 2022 | -6.8% | -9.2% | -8.3% | |
| Q1 2022 | -1.4% | -1.0% | +0.8% | |
| Q4 2021 | +5.1% | +5.8% | +3.8% | |
| Q3 2021 | +9.2% | +9.0% | +9.4% | |
| Q2 2021 | -4.4% | -0.4% | -2.4% | |
| Q1 2021 | +1.5% | +2.3% | +6.1% | |
| Q4 2020 | -0.8% | -6.7% | -3.9% | |
| Q3 2020 | +1.2% | +3.5% | +0.2% | |
| Q2 2020 | +9.0% | +10.3% | +12.2% | |
| Q1 2020 | -3.9% | -6.5% | +5.6% | |
| Q4 2019 | +3.2% | -1.2% | -23.1% | |
| Q3 2019 | -1.7% | +0.6% | +5.9% | |
| Q2 2019 | +3.7% | +8.1% | +13.9% | |
| Q1 2019 | -0.6% | +0.7% | +0.3% | |
| Q4 2018 | +1.3% | +2.8% | +1.9% | |
| Q3 2018 | +6.2% | +6.6% | +7.6% | |
| Q2 2018 | +0.4% | -2.5% | +0.1% | |
| Q1 2018 | +3.0% | +3.3% | +13.4% | |
| Q4 2017 | +2.4% | +2.1% | +12.9% | |
| Q3 2017 | +9.1% | +5.0% | +12.7% | |
| Q2 2017 | -1.1% | -2.3% | -6.3% | |
| Q1 2017 | +10.0% | +9.4% | +9.0% | |
| Q4 2016 | +1.9% | +2.0% | +9.1% | |
| Q3 2016 | -0.3% | +1.8% | +6.3% | |
| Q2 2016 | +5.0% | +3.0% | -7.9% | |
| Q1 2016 | -6.7% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | +13.0% | — | — | |
| Q2 2015 | +5.1% | — | — | |
| Q1 2015 | -4.7% | — | — | |
| Q4 2014 | +7.5% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | +4.3% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | +10.5% | — | — | |
| Q3 2013 | -5.2% | — | — | |
| Q2 2013 | -7.3% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2012 | +4.9% | — | — | |
| Q3 2012 | -2.0% | — | — | |
| Q2 2012 | +5.1% | — | — | |
| Q1 2012 | +2.9% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -5.8% | — | — | |
| Q1 2010 | -2.6% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q2 2009 | -0.9% | — | — | |
| Q4 2009 | -0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro